The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.
 
Kim Anna Reiss
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; Lilly (Inst); Tesaro (Inst)
 
Rosemarie Mick
Stock and Other Ownership Interests - Editas Medicine
Consulting or Advisory Role - Infiniti Medical
 
Mark H. O'Hara
Consulting or Advisory Role - Exelixis; Karyopharm Therapeutics
Research Funding - Bristol-Myers Squibb; Celldex; Lilly; Parker Institute for Cancer Immunotherapy
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Ursina R. Teitelbaum
No Relationships to Disclose
 
Thomas Benjamin Karasic
Research Funding - Celgene; H3 Biomedicine; Syndax; Taiho Pharmaceutical
 
Charles John Schneider
No Relationships to Disclose
 
Peter J. O'Dwyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Genentech
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics
 
Danielle Karlson
No Relationships to Disclose
 
Stacy Cowden
No Relationships to Disclose
 
Mary Jane Fuhrer
No Relationships to Disclose
 
Erica L. Carpenter
Honoraria - AstraZeneca
Research Funding - Becton Dickinson; Janssen; Merck
Patents, Royalties, Other Intellectual Property - Invention disclosure entitled, "Methods and Compositions for Identifying, Diagnosing and Treating Neuroblastoma"; Invention disclosure entitled, "Methods and Compositions for Identifying, Diagnosing and Treating Neuroblastoma"; Invention disclosure entitled, "Methods and Compositions for Treating Neuroblastoma"
Travel, Accommodations, Expenses - AstraZeneca; Foundation Medicine
 
Austin A Pantel
No Relationships to Disclose
 
Mehran Makvandi
No Relationships to Disclose
 
David A. Mankoff
Consulting or Advisory Role - Blue Earth Diagnostics; GE Healthcare
Research Funding - Siemens Healthcare Diagnostics
Other Relationship - ImaginAb; Reflexion Medical
 
Katharine Nathanson
No Relationships to Disclose
 
Kara Noelle Maxwell
No Relationships to Disclose
 
Gregory Lawrence Beatty
Stock and Other Ownership Interests - Advaxis; Johnson & Johnson
Honoraria - Incyte; Janssen
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Genmab; Incyte; Janssen; Merck; Opsona Therapeutics; Seagen; Vaccinex
Research Funding - Biothera; Bristol-Myers Squibb; Halozyme; Incyte; Janssen; Newlink Genetics; Novartis; Verastem
Patents, Royalties, Other Intellectual Property - Inventor of intellectual property related to mesothelin CAR T cells that is licensed by the University of Pennsylvania to Novartis.
 
Susan M. Domchek
Honoraria - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Pharmamar (Inst)